Table 2

Proptosis measurements for patients

Study phase	Case	Baseline study eye	Week 24 study eye	Baseline fellow eye	Week 24 fellow eye	Baseline asymmetry	Week 24 asymmetry
A: Teprotumumab group
3	1	27	20	17	17	10	3
3	2	23	18	18	17	5	1
3	3	26	20	23	18.5	3	1.5
2	4	26	21	22	21	4	0
2	5	24	20	20	19	4	1
2	6	26	20	23	21	3	1
2	7	25	21	22	19	3	2
2	8	21	16	15	12	6	4
2	9	23	19	18	18	5	1
2	10	22	21	19	16	3	5
Mean		24.2	19.6	19.55	17.85	4.64	1.75
SD		1.9	21.58	2.66	2.63	2.06	1.81
B: Placebo group
3	1	28	28	24	24	4	4
3	2	21	19	18	18	3	1
3	3	20	20	17	18	3	2
3	4	25	26	22	23	3	3
3	5	21	21	17	18	4	3
3	6	24	24	19	20	5	4
2	7	24	21	21	19	3	2
2	8	16	17	12	16	4	1
2	9	19	21	16	17	3	4
2	10	28	30	25	25	3	5
2	11	25	25	22	23	3	2
2	12	22	23	18	17	4	6
Mean		22.8	23	19.3	19.8	3.5	3.1
SD		3.6	3.9	3.7	3.1	0.7	1.6